The lancet. HIV

The most recent articles from: Lancet HIV November 2017

The lancet. HIV · Nov 2017

Editorial

U=U taking off in 2017.

no abstract available

read more… or not…
The lancet. HIV · Nov 2017

Randomized Controlled Trial

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. ⋯ Merck & Co, Inc.

read on… or not…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.